Table 5.
Comparisons of plasma biomarker levels (pg/mL) between patients with and without PSCI
| Total (n = 193) | PSCI (n = 66) | Without PSCI (n = 127) | P-value | |
|---|---|---|---|---|
| NT-pro-BNP | 393.4 (103.4–1023.0) | 671.0 (132.9–1383.9) | 305.0 (84.0–876.0) | 0.027 |
| LMP2 | 645.8 (436.7–822.9) | 685.1 (536.8–1074.9) | 615.8 (322.9–764.7) | 0.003 |
| LMP5 | 408.6 (316.3–576.6) | 409.4 (315.3–675.0) | 403.8 (316.2–557.1) | 0.577 |
| LMP7 | 288.9 (212.4–435.7) | 304.1 (239.8–573.3) | 286.3 (197.6–393.9) | 0.052 |
Date are expressed as medians with interquartile ranges and analyzed using the Kruskal-Wallis H test. LMP: Low molecular mass peptide; NT-pro-BNP: N-terminal pro-B-type natriuretic peptide; PSCI: post-stroke cognitive impairment.